Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
PDL BioPharma is a biotechnology business based in the US. PDL BioPharma stocks (PDLI.US) are listed on the NASDAQ and all prices are listed in US Dollars. PDL BioPharma employs 109 staff and has a trailing 12-month revenue of around $27.8 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|52-week range||$2.39 - $2.84|
|50-day moving average||$2.58|
|200-day moving average||$2.80|
|Wall St. target price||$2.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.01|
Note: The dollar amounts in the table below are in Canadian dollars.
Valuing PDL BioPharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PDL BioPharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PDL BioPharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 477x. In other words, PDL BioPharma shares trade at around 477x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PDL BioPharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PDL BioPharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$27.8 million|
|Gross profit TTM||$13.4 million|
|Return on assets TTM||-4.1%|
|Return on equity TTM||-7.36%|
|Market capitalisation||$282.1 million|
TTM: trailing 12 months
We're not expecting PDL BioPharma to pay a dividend over the next 12 months.
PDL BioPharma's shares were split on a 2:1 basis on 10 October 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your PDL BioPharma shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for PDL BioPharma shares which in turn could have impacted PDL BioPharma's share price.
Over the last 12 months, PDL BioPharma's shares have ranged in value from as little as $2.39 up to $2.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PDL BioPharma's is 1.1407. This would suggest that PDL BioPharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.
We break down how the CRA treats stock gains and losses, how foreign stocks are taxed, which trading expenses are tax-deductible and more.Read more…
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
Everything we know about the Intensity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Incannex Healthcare Limited IPO, plus information on how to buy in.
Everything we know about the Genenta Science SpA IPO, plus information on how to buy in.
We’ve pulled a list together of the top trending stocks being mentioned on Twitter over the past 24 hours.
Everything we know about the Polestar IPO, plus information on how to buy in.
Everything we know about the Knightscope IPO, plus information on how to buy in.
Everything we know about the Sangoma Technologies Corporation IPO, plus information on how to buy in.
Everything we know about the Sweetgreen IPO, plus information on how to buy in.
Everything we know about the UserTesting IPO, plus information on how to buy in.
Everything we know about the Sono Motors IPO, plus information on how to buy in.
You must be logged in to post a comment.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.